Web Desc
Cancer Immunology and Immunotherapy
joint with Antibodies as Drugs
Organizer(s): Glenn Dranoff, Carl H. June and Suzanne L. Topalian
Date: January 27 - February 01, 2013
Location: Fairmont Hotel Vancouver, Vancouver, BC, Canada
Sponsored by Bayer USA Foundation and Bristol-Myers Squibb Company. Supported by an educational donation provided by Amgen.
Summary of Meeting:
The recent FDA approvals of Provenge® as the first therapeutic cancer vaccine and Ipilimumab® as the first monoclonal antibody that blocks negative immune regulation are landmark achievements that highlight substantive progress in cancer immunology. These novel treatments derive from the cumulative insights of basic and translational scientists into the mechanisms of protective tumor immunity in cancer patients. Advances in genetic, cellular and biochemical technologies have dramatically increased our understanding of the pathways through which the host responds to cancer. Tumor-host interactions in the microenvironment are increasingly recognized to play a critical role in determining disease inhibition or promotion. This Keystone Symposia meeting will bring together leading cancer immunologists to discuss their most recent insights into immune recognition, regulation, tumor escape and therapeutic manipulation. Emerging areas of cancer metabolism and material science engineering that relate to cancer immunology will be highlighted. The integration of basic and clinical aspects of tumor immunity in this meeting should stimulate interest from a wide array of investigators and students. The concurrent meeting on Antibodies as Drugs will underscore the increasing connections between these fields, and potentially accelerate the development of new cancer immunotherapies.
Scholarship Deadline: September 25 2012
Discounted Abstract Deadline: September 25 2012
Abstract Deadline: October 25 2012
Discounted Registration Deadline: November 27 2012
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
Educational donation provided by AmgenBayer USA FoundationBristol-Myers Squibb Company
We gratefully acknowledge additional support for this conference from:
Cell Signaling Technology, Inc.Landes BioscienceMyriad-RBM
Ono Pharmaceutical Co. Ltd.
STEMCELL Technologies, Inc.
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Immunocore Limited

Micromet, Inc.
$1 - $2,499

Cancer Immunity

Molecular Metabolism (Elsevier GmbH)
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Cancer Immunity
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Sunday, January 27 | 3:00PM - 7:30PM
Arrival and Registration
Room: British/Columbia Foyer


Sunday, January 27 | 6:15PM - 7:15PM
Refreshments
Room: British/Columbia Foyer


Sunday, January 27 | 7:15PM - 8:30PM
Welcome and Keynote Address
Room: Columbia Ballroom

Speaker 1 of 2
* Glenn Dranoff, Novartis Institutes for BioMedical Research, USA

Sunday, January 27 | 7:15PM - 8:30PM
Welcome and Keynote Address
Room: Columbia Ballroom

Speaker 2 of 2
James P. Allison, University of Texas MD Anderson Cancer Center, USA
Checkpoint Blockade

Monday, January 28 | 6:45AM - 8:00AM
Breakfast
Room: Pacific Ballroom


Monday, January 28 | 8:00AM - 11:00AM
Tumor Targeting - From Understanding Mechanisms to New Targe
ting Agents (Joint)

Room: British/Columbia Ballroom

Speaker 1 of 6
* Dario Neri, ETH Zürich, Switzerland

Monday, January 28 | 8:00AM - 11:00AM
Tumor Targeting - From Understanding Mechanisms to New Targe
ting Agents (Joint)

Room: British/Columbia Ballroom

Speaker 2 of 6
Karl Dane Wittrup, Massachusetts Institute of Technology, USA
Synergistic Antibody and Cytokine Effects in Cancer Immunotherapy

Monday, January 28 | 8:00AM - 11:00AM
Tumor Targeting - From Understanding Mechanisms to New Targe
ting Agents (Joint)

Room: British/Columbia Ballroom

Speaker 3 of 6
Kerry A. Chester, University College London Cancer Institute, UK
Antibody-Targeted Nanoparticles for Cancer Treatment

Monday, January 28 | 8:00AM - 11:00AM
Tumor Targeting - From Understanding Mechanisms to New Targe
ting Agents (Joint)

Room: British/Columbia Ballroom

Speaker 4 of 6
Erkki Ruoslahti, Sanford-Burnham Medical Research Institute, USA
Increasing Extravasation with Peptides

Monday, January 28 | 8:00AM - 11:00AM
Tumor Targeting - From Understanding Mechanisms to New Targe
ting Agents (Joint)

Room: British/Columbia Ballroom

Speaker 5 of 6
Anna M. Wu, University of California, Los Angeles, USA
Engineered Antibodies for Molecular Imaging of Cancer

Monday, January 28 | 8:00AM - 11:00AM
Tumor Targeting - From Understanding Mechanisms to New Targe
ting Agents (Joint)

Room: British/Columbia Ballroom

Speaker 6 of 6
Henry B. Lowman, CytomX, USA
Short Talk: Probody™ Therapeutics: A New Class of Proteolytically Activated Antibodies

Monday, January 28 | 9:20AM - 9:40AM
Coffee Break
Room: British/Columbia Foyer


Monday, January 28 | 10:00AM - 10:00AM
On Own for Lunch and Recreation


Monday, January 28 | 11:00AM - 1:00PM
Poster Setup
Room: Pacific Ballroom


Monday, January 28 | 1:00PM - 10:00PM
Poster Viewing
Room: Pacific Ballroom


Monday, January 28 | 2:30PM - 4:30PM
Workshop 1: Emerging Antibody Generation Methods
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 1 of 8
* James D. Marks, University of California, San Francisco, USA


Monday, January 28 | 2:30PM - 4:30PM
Workshop 1: Emerging Antibody Generation Methods
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 2 of 8
Filippa Fleetwood, Royal Institute of Technology, Sweden
Surface Display of a Single-Domain Antibody Library on Gram-Positive Bacteria


Monday, January 28 | 2:30PM - 4:30PM
Workshop 1: Emerging Antibody Generation Methods
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 3 of 8
Christian Kunz, MorphoSys AG, Germany
The Role of HuCAL in the Discovery of Lead Antibodies with a Unique MoA


Monday, January 28 | 2:30PM - 4:30PM
Workshop 1: Emerging Antibody Generation Methods
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 4 of 8
Audrey D. McConnell, AnaptysBio, Inc., USA
High Affinity Humanized Antibodies without Making Hybridomas; Immunization Paired with Mammalian Cell Display and in vitro Somatic Hypermutation


Monday, January 28 | 2:30PM - 4:30PM
Workshop 1: Emerging Antibody Generation Methods
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 5 of 8
Amandeep K. Gakhal, Sutro Biopharma, USA
A New Method for Direct Selection of Synthetic Antibody Fragments on Cell Surface Targets from a Phage-Displayed Library


Monday, January 28 | 2:30PM - 4:30PM
Workshop 1: Emerging Antibody Generation Methods
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 6 of 8
E-Chiang Lee, Kymab, UK
Development of a Next-Generation in vivo mAb Discovery Platform


Monday, January 28 | 2:30PM - 4:30PM
Workshop 1: Emerging Antibody Generation Methods
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 7 of 8
Hiroshi Hamana, University of Toyama, Japan
Rabbit ISSAC (Rabbit Immunospot Array Assay on a Chip) Allows for the Rapid Generation of Rabbit Monoclonal Antibodies with High Affinity


Monday, January 28 | 2:30PM - 4:30PM
Workshop 1: Emerging Antibody Generation Methods
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 8 of 8
Kai Zhu, Schrodinger Inc., USA
Ab initio Structure Prediction of the Antibody Hypervariable H3 Loop


Monday, January 28 | 4:30PM - 5:00PM
Coffee Available
Room: British/Columbia Foyer


Monday, January 28 | 5:00PM - 7:00PM
Tumor Microenvironment
Room: Columbia Ballroom

Speaker 1 of 5
* James P. Allison, University of Texas MD Anderson Cancer Center, USA

Monday, January 28 | 5:00PM - 7:00PM
Tumor Microenvironment
Room: Columbia Ballroom

Speaker 2 of 5
Wolf-Hervé Fridman, Cordeliers Research Centre, France
The Immune Microenvironment of Primary and Metastatic Human Tumors

Monday, January 28 | 5:00PM - 7:00PM
Tumor Microenvironment
Room: Columbia Ballroom

Speaker 3 of 5
Robert D. Schreiber, Washington University School of Medicine, USA
Cancer Immunoediting: Antigens, Mechanisms and Implications for Cancer Immunotherapy


Monday, January 28 | 5:00PM - 7:00PM
Tumor Microenvironment
Room: Columbia Ballroom

Speaker 4 of 5
Nikhil S. Joshi, Yale University School of Medicine, USA
Short Talk: Effector Regulatory T Cell Differentiation during Autochthonous Mouse Lung Adenocarcinoma Development

Monday, January 28 | 5:00PM - 7:00PM
Tumor Microenvironment
Room: Columbia Ballroom

Speaker 5 of 5
Drew M. Pardoll, Johns Hopkins University School of Medicine, USA
Inflammation and Cancer

Monday, January 28 | 5:00PM - 7:00PM
Payloaded Antibodies for Cancer Treatment
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 1 of 4
* Peter D. Senter, Seattle Genetics Inc., USA
Empowered Antibodies for Cancer Therapy


Monday, January 28 | 5:00PM - 7:00PM
Payloaded Antibodies for Cancer Treatment
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 2 of 4
Dario Neri, ETH Zürich, Switzerland
Armed Antibodies for Vascular Targeting


Monday, January 28 | 5:00PM - 7:00PM
Payloaded Antibodies for Cancer Treatment
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 3 of 4
Paul G. Polakis, Genentech, Inc., USA
Antibody Drug Conjugates for the Treatment of Cancer


Monday, January 28 | 5:00PM - 7:00PM
Payloaded Antibodies for Cancer Treatment
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 4 of 4
Brian J. Agnew, Thermo Fisher Scientific, USA
Short Talk: Site-Selective Antibody Labeling without Engineering: Answering Unmet Needs in Antibody Payload Conjugation


Monday, January 28 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Pacific Ballroom


Monday, January 28 | 7:30PM - 10:00PM
Poster Session 1
Room: Pacific Ballroom


Tuesday, January 29 | 6:45AM - 8:00AM
Breakfast
Room: Pacific Ballroom


Tuesday, January 29 | 8:00AM - 11:15AM
Engineering and Immunotherapy
Room: Columbia Ballroom

Speaker 1 of 7
* Suzanne L. Topalian, Johns Hopkins University School of Medicine, USA

Tuesday, January 29 | 8:00AM - 11:15AM
Engineering and Immunotherapy
Room: Columbia Ballroom

Speaker 2 of 7
David J. Mooney, Harvard University, USA
Polymer Scaffolds for immunotherapy

Tuesday, January 29 | 8:00AM - 11:15AM
Engineering and Immunotherapy
Room: Columbia Ballroom

Speaker 3 of 7
Darrell J. Irvine, Massachusetts Institute of Technology, USA
Interfacing Nanoparticle Drug Carriers with Lymphocytes to Enhance Cellular Immunotherapy

Tuesday, January 29 | 8:00AM - 11:15AM
Engineering and Immunotherapy
Room: Columbia Ballroom

Speaker 4 of 7
Carl H. June, University of Pennsylvania, USA
Engineered T Cells for Adoptive Therapy

Tuesday, January 29 | 8:00AM - 11:15AM
Engineering and Immunotherapy
Room: Columbia Ballroom

Speaker 5 of 7
Hollie J. Jackson, Memorial Sloan Ketter Cancer Center, USA
Short Talk: Expansion and Modification of Umbilical Cord Blood T Cells with a Chimeric Antigen Receptor and IL-12

Tuesday, January 29 | 8:00AM - 11:15AM
Engineering and Immunotherapy
Room: Columbia Ballroom

Speaker 6 of 7
Sheena N. Smith, University of Zurich, Switzerland
Short Talk: Engineering Designer T Cell Receptors through the Use of Single-Chain T Cell Receptor Scaffolds

Tuesday, January 29 | 8:00AM - 11:15AM
Engineering and Immunotherapy
Room: Columbia Ballroom

Speaker 7 of 7
Laurence J. N. Cooper, ZIOPHARM Oncology, Inc., USA
Sleeping Beauty Transposition for Engineered T Cells

Tuesday, January 29 | 8:00AM - 11:15AM
Antibodies in Infectious Diseases
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 1 of 5
Antonio Lanzavecchia, Institute for Research in Biomedicine, Switzerland
Human Antibodies to Infectious Disease Targets


Tuesday, January 29 | 8:00AM - 11:15AM
Antibodies in Infectious Diseases
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 2 of 5
* Dennis R. Burton, The Scripps Research Institute, USA
Broadly Neutralizing Antibodies to Identify Vaccine Targets on HIV


Tuesday, January 29 | 8:00AM - 11:15AM
Antibodies in Infectious Diseases
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 3 of 5
Gary J. Nabel, Sanofi, USA
Broadly Neutralizing Antibodies to HIV: A Model for Prevention and Treatment of an Infectious Disease


Tuesday, January 29 | 8:00AM - 11:15AM
Antibodies in Infectious Diseases
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 4 of 5
Erica Ollmann Saphire, La Jolla Institute for Immunology, USA
Antibodies Against the Filoviruses


Tuesday, January 29 | 8:00AM - 11:15AM
Antibodies in Infectious Diseases
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 5 of 5
George Georgiou, University of Texas at Austin, USA
Proteomic Deconvolution of the Human Serological IgG Repertoire in Vaccine Evaluation and Antibody Discovery


Tuesday, January 29 | 9:20AM - 9:40AM
Coffee Break
Room: British/Columbia Foyer


Tuesday, January 29 | 10:00AM - 10:00AM
On Own for Lunch and Recreation


Tuesday, January 29 | 11:15AM - 1:00PM
Poster Setup
Room: Pacific Ballroom


Tuesday, January 29 | 1:00PM - 10:00PM
Poster Viewing
Room: Pacific Ballroom


Tuesday, January 29 | 4:30PM - 5:00PM
Coffee Available
Room: British/Columbia Foyer


Tuesday, January 29 | 5:00PM - 7:00PM
Cancer Vaccines
Room: Columbia Ballroom

Speaker 1 of 5
* Carl H. June, University of Pennsylvania, USA

Tuesday, January 29 | 5:00PM - 7:00PM
Cancer Vaccines
Room: Columbia Ballroom

Speaker 2 of 5
Cornelia Liu Trimble, Johns Hopkins University School of Medicine, USA
Tissue T Cells in HPV Disease

Tuesday, January 29 | 5:00PM - 7:00PM
Cancer Vaccines
Room: Columbia Ballroom

Speaker 3 of 5
Cornelis J. M. Melief, Leiden University Medical Center & ISA Pharmaceuticals BV, Netherlands
Chemo-Immunotherapy of High Risk HPV Infections

Tuesday, January 29 | 5:00PM - 7:00PM
Cancer Vaccines
Room: Columbia Ballroom

Speaker 4 of 5
Marieke Griffioen, Leiden University Medical Center, Netherlands
Short Talk: Intercellular Transfer of Natural HLA Class II Ligands Is Mediated by Full Length Proteins with Abundant Cellular Expression that Are Sequestered and Secreted into Microvesicles

Tuesday, January 29 | 5:00PM - 7:00PM
Cancer Vaccines
Room: Columbia Ballroom

Speaker 5 of 5
David H. Kirn, Jennerex, USA
Targeted Oncolytic and Immunotherapeutic Viruses: Emerging Multi-Mechanistic Biologics for Cancer

Tuesday, January 29 | 5:00PM - 7:00PM
New Technologies for Generating Proteins with Novel Function
s
This session is from Antibodies as Drugs

Room: British Ballroom

Speaker 1 of 5
* Andreas G. Plückthun, University of Zürich, Switzerland


Tuesday, January 29 | 5:00PM - 7:00PM
New Technologies for Generating Proteins with Novel Function
s
This session is from Antibodies as Drugs

Room: British Ballroom

Speaker 2 of 5
David Baker, University of Washington, USA
Computational Protein Design and Protein Therapeutics


Tuesday, January 29 | 5:00PM - 7:00PM
New Technologies for Generating Proteins with Novel Function
s
This session is from Antibodies as Drugs

Room: British Ballroom

Speaker 3 of 5
Andrew D. Ellington, University of Texas at Austin, USA
Rational Engineering of Antibodies for Affinity and Stability


Tuesday, January 29 | 5:00PM - 7:00PM
New Technologies for Generating Proteins with Novel Function
s
This session is from Antibodies as Drugs

Room: British Ballroom

Speaker 4 of 5
Julia Shifman, Hebrew University of Jerusalem, Israel
Computational Design of Protein-Protein Interactions


Tuesday, January 29 | 5:00PM - 7:00PM
New Technologies for Generating Proteins with Novel Function
s
This session is from Antibodies as Drugs

Room: British Ballroom

Speaker 5 of 5
Romain Rouet, University of California, Berkeley, USA
Short Talk: Stability Engineering of Human Antibody Therapeutics


Tuesday, January 29 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Pacific Ballroom


Tuesday, January 29 | 7:30PM - 10:00PM
Poster Session 2
Room: Pacific Ballroom


Wednesday, January 30 | 6:45AM - 8:00AM
Breakfast
Room: Pacific Ballroom


Wednesday, January 30 | 7:30AM - 8:00AM
Poster Setup
Room: Pacific Ballroom


Wednesday, January 30 | 8:00AM - 5:00PM
Poster Viewing
Room: Pacific Ballroom


Wednesday, January 30 | 8:00AM - 11:15AM
Adoptive Cellular Therapy
Room: Columbia Ballroom

Speaker 1 of 7
* Laurence Zitvogel, Institut Gustave Roussy, France

Wednesday, January 30 | 8:00AM - 11:15AM
Adoptive Cellular Therapy
Room: Columbia Ballroom

Speaker 2 of 7
Stanley R. Riddell, Fred Hutchinson Cancer Research Center, University of Washington, USA
Chimeric Antigen Receptor Design and T Cell Subsets in Adoptive Therapy

Wednesday, January 30 | 8:00AM - 11:15AM
Adoptive Cellular Therapy
Room: Columbia Ballroom

Speaker 3 of 7
Kazuhiro Kakimi, University of Tokyo Hospital, Japan
Short Talk: Autologous gammadelta T Cell Transfer Therapy for the Treatment of Solid Cancer

Wednesday, January 30 | 8:00AM - 11:15AM
Adoptive Cellular Therapy
Room: Columbia Ballroom

Speaker 4 of 7
Nicholas P. Restifo, Lyell, USA
Memory T Cells Precede Effector Cells: Why it Matters for ACT

Wednesday, January 30 | 8:00AM - 11:15AM
Adoptive Cellular Therapy
Room: Columbia Ballroom

Speaker 5 of 7
Catherine M. Bollard, Children’s National Health System, USA
T Cell Therapies for EBV+ Lymphomas – Where Have We Come From and Where Are We Going?

Wednesday, January 30 | 8:00AM - 11:15AM
Adoptive Cellular Therapy
Room: Columbia Ballroom

Speaker 6 of 7
Yanxia Guo, Bristol-Myers Squibb, USA
Short Talk: Retinoic Acid-Rich Microenvironment Provides Clonal Survival Cues for Tumor and Bacteria-Specific CD8+ T Cells

Wednesday, January 30 | 8:00AM - 11:15AM
Adoptive Cellular Therapy
Room: Columbia Ballroom

Speaker 7 of 7
Robert S. Negrin, Stanford University, USA
Immunobiology of Allogeneic Hematopoietic Cell Transplantation

Wednesday, January 30 | 8:00AM - 11:00AM
Modulating the Activity of Growth Factor Receptors
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 1 of 6
* Karl Dane Wittrup, Massachusetts Institute of Technology, USA


Wednesday, January 30 | 8:00AM - 11:00AM
Modulating the Activity of Growth Factor Receptors
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 2 of 6
Ermanno Gherardi, University of Pavia, Italy
Structure/Function and Therapeutic Targeting of HGF/SF and MET


Wednesday, January 30 | 8:00AM - 11:00AM
Modulating the Activity of Growth Factor Receptors
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 3 of 6
Andreas G. Plückthun, University of Zürich, Switzerland
Engineering Receptor Ligands for Powerful Cellular Responses


Wednesday, January 30 | 8:00AM - 11:00AM
Modulating the Activity of Growth Factor Receptors
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 4 of 6
Yosef Yarden, Weizmann Institute of Science, Israel
Antibodies to EGFR Family as Drugs


Wednesday, January 30 | 8:00AM - 11:00AM
Modulating the Activity of Growth Factor Receptors
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 5 of 6
Carlos F. Barbas III, The Scripps Research Institute, USA
Multifunctional and Multi-Specific Antibodies: Single-Protein Combination Therapeutics


Wednesday, January 30 | 8:00AM - 11:00AM
Modulating the Activity of Growth Factor Receptors
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 6 of 6
Klaus Koefoed, Symphogen A/S, Denmark
Short Talk: In vitro Comparison of EGFR/Her3 Targeting Antibody Mixtures and Bispecific MEHD7945A Analogue Shows More Efficacious Inhibition by Mixtures, Even Under Conditions Mimicking Cancer Resistance


Wednesday, January 30 | 9:20AM - 9:40AM
Coffee Break
Room: British/Columbia Foyer


Wednesday, January 30 | 11:15AM - 12:00PM
Lunch
Room: Pacific Ballroom


Wednesday, January 30 | 12:00PM - 2:30PM
Poster Session 3
Room: Pacific Ballroom


Wednesday, January 30 | 2:30PM - 4:30PM
Workshop: Advances in Cancer Immunology
Room: Columbia Ballroom

Speaker 1 of 7
* Wolf-Hervé Fridman, Cordeliers Research Centre, France

Wednesday, January 30 | 2:30PM - 4:30PM
Workshop: Advances in Cancer Immunology
Room: Columbia Ballroom

Speaker 2 of 7
Sally Amos, BC Cancer Agency, Canada
Human Bilateral Breast Cancer: A Unique Opportunity to Examine Behaviors of Tumor-Infiltrating Lymphocytes

Wednesday, January 30 | 2:30PM - 4:30PM
Workshop: Advances in Cancer Immunology
Room: Columbia Ballroom

Speaker 3 of 7
Sarah Q. Crome, University Health Network, Canada
Regulatory Natural Killer Cells Inhibit Anti-Tumour T Cells

Wednesday, January 30 | 2:30PM - 4:30PM
Workshop: Advances in Cancer Immunology
Room: Columbia Ballroom

Speaker 4 of 7
Connie Duong, Peter MacCallum Cancer Centre, Australia
Generating Stronger T Cells for Adoptive Immunotherapy

Wednesday, January 30 | 2:30PM - 4:30PM
Workshop: Advances in Cancer Immunology
Room: Columbia Ballroom

Speaker 5 of 7
Daniel T. Fisher, Roswell Park Cancer Institute, USA
Thermal Activation of IL-6 Trans-Signaling Licenses Mouse and Human Tumor Microvascular Gateways for Trafficking of Cytotoxic T Cells

Wednesday, January 30 | 2:30PM - 4:30PM
Workshop: Advances in Cancer Immunology
Room: Columbia Ballroom

Speaker 6 of 7
Richard P. Junghans, Roger Williams Hospital, USA
Phase I Trial Data in Prostate Cancer Suggest Critical Role for IL2 Adjunctive Co-Therapy for Successful Suppression of Solid Tumor with Designer T Cells

Wednesday, January 30 | 2:30PM - 4:30PM
Workshop: Advances in Cancer Immunology
Room: Columbia Ballroom

Speaker 7 of 7
Brian Ruffell, Oregon Health & Science University, USA
Macrophages Regulate Response to Chemotherapy in Mammary Carcinomas

Wednesday, January 30 | 2:30PM - 4:30PM
Workshop 2: Enhancing Effector Functions and Extending Half-
Life
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 1 of 6
* Henry B. Lowman, CytomX, USA


Wednesday, January 30 | 2:30PM - 4:30PM
Workshop 2: Enhancing Effector Functions and Extending Half-
Life
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 2 of 6
Javier Chaparro-Riggers, Rinat-Pfizer Inc., USA
Improving PK and Cholesterol Lowering by a pH-Sensitive Anti-PCSK9-Antibody


Wednesday, January 30 | 2:30PM - 4:30PM
Workshop 2: Enhancing Effector Functions and Extending Half-
Life
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 3 of 6
Jonathan Sockolosky, University of California, San Francisco, USA
Engineering FcRn-Mediated Recycling and Transcytosis in Recombinant Proteins by Short Terminal Peptide Extensions


Wednesday, January 30 | 2:30PM - 4:30PM
Workshop 2: Enhancing Effector Functions and Extending Half-
Life
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 4 of 6
Tomoyuki Igawa, Chugai Pharmabody Research, Singapore
Engineered Antibody Fc Variant with Selectively Enhanced FcgammaRIIb Binding Over Both FcgammaRIIaR131 and FcgammaRIIaH131


Wednesday, January 30 | 2:30PM - 4:30PM
Workshop 2: Enhancing Effector Functions and Extending Half-
Life
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 5 of 6
Elizabeth L. Smith, University of California, Berkeley, USA
Antibody Glycoengineering with Aldehyde Tag Technology


Wednesday, January 30 | 2:30PM - 4:30PM
Workshop 2: Enhancing Effector Functions and Extending Half-
Life
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 6 of 6
Surjit B. Dixit, Zymeworks Inc., Canada
AlbuCORE™ – Structure-Guided Engineering and Design of a Multi-Valent Albumin Scaffold


Wednesday, January 30 | 4:30PM - 5:00PM
Coffee Available
Room: British/Columbia Foyer


Wednesday, January 30 | 5:00PM - 7:00PM
Metabolism and Cancer
Room: Columbia Ballroom

Speaker 1 of 5
* Stanley R. Riddell, Fred Hutchinson Cancer Research Center, University of Washington, USA

Wednesday, January 30 | 5:00PM - 7:00PM
Metabolism and Cancer
Room: Columbia Ballroom

Speaker 2 of 5
Laurence Zitvogel, Institut Gustave Roussy, France
Role of Type 1 IFN and dsRNA Sensors in the T Cell-Dependent Efficacy of Chemotherapy

Wednesday, January 30 | 5:00PM - 7:00PM
Metabolism and Cancer
Room: Columbia Ballroom

Speaker 3 of 5
Vincenzo Bronte, University of Verona, Italy
Myeloid Derived Suppressor Cells

Wednesday, January 30 | 5:00PM - 7:00PM
Metabolism and Cancer
Room: Columbia Ballroom

Speaker 4 of 5
George C. Prendergast, Lankenau Institute for Medical Research, USA
IDO Pathways and Targeting

Wednesday, January 30 | 5:00PM - 7:00PM
Metabolism and Cancer
Room: Columbia Ballroom

Speaker 5 of 5
Courtney Crane, University of Washington, USA
Short Talk: Tumor Derived Lactate Dehydrogenase Drives Innate Immune Cell Crosstalk in Patients

Wednesday, January 30 | 5:00PM - 7:15PM
Bispecific and Multispecific Targeting Agents
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 1 of 6
* Paul Carter, Genentech, Inc., USA


Wednesday, January 30 | 5:00PM - 7:15PM
Bispecific and Multispecific Targeting Agents
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 2 of 6
Kaspar Binz, Molecular Partners, Switzerland
Exploiting Novel Therapeutic Mechanisms Using Multi-Specific DARPins


Wednesday, January 30 | 5:00PM - 7:15PM
Bispecific and Multispecific Targeting Agents
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 3 of 6
James D. Marks, University of California, San Francisco, USA
Development and Mechanism of Action of mAb Combinations that Potently Neutralize Botlinum Neurotoxin


Wednesday, January 30 | 5:00PM - 7:15PM
Bispecific and Multispecific Targeting Agents
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 4 of 6
Lutz Jermutus, MedImmune LLC, UK
A Novel Multi-Mechanistic Monoclonal Antibody Format for Treating Pseudomonas aeruginosa Infections


Wednesday, January 30 | 5:00PM - 7:15PM
Bispecific and Multispecific Targeting Agents
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 5 of 6
Janine Schuurman, Genmab B.V., Netherlands
Short Talk: Efficient Generation of Stable Bispecific IgG1 by Controlled Fab-Arm Exchange


Wednesday, January 30 | 5:00PM - 7:15PM
Bispecific and Multispecific Targeting Agents
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 6 of 6
David Poon, Zymeworks Inc., Canada
Short Talk: Azymetric™ Scaffold – Optimized Fc Heterodimer for Improved Purity and Stability in the Development of Bispecific Antibodies


Wednesday, January 30 | 7:00PM - 7:00PM
On Own for Dinner


Thursday, January 31 | 6:45AM - 8:00AM
Breakfast
Room: Pacific Ballroom


Thursday, January 31 | 8:00AM - 11:15AM
Immunomodulatory Antibody Therapies (Joint)
Room: British/Columbia Ballroom

Speaker 1 of 7
* George J. Weiner, University of Iowa, USA

Thursday, January 31 | 8:00AM - 11:15AM
Immunomodulatory Antibody Therapies (Joint)
Room: British/Columbia Ballroom

Speaker 2 of 7
Suzanne L. Topalian, Johns Hopkins University School of Medicine, USA
PD-1 Blockade in Cancer Therapy

Thursday, January 31 | 8:00AM - 11:15AM
Immunomodulatory Antibody Therapies (Joint)
Room: British/Columbia Ballroom

Speaker 3 of 7
Li Wang, Medical College of Wisconsin, USA
Short Talk: Targeting a Novel Immune Checkpoint Protein VISTA Alters Tumor Microenvironment and Synergizes with Cancer Vaccine to Eradicate Established Melanoma

Thursday, January 31 | 8:00AM - 11:15AM
Immunomodulatory Antibody Therapies (Joint)
Room: British/Columbia Ballroom

Speaker 4 of 7
Nils Lonberg, Canaan Partners, USA
Development Hurdles for Immuno-Oncology Antibody Drugs

Thursday, January 31 | 8:00AM - 11:15AM
Immunomodulatory Antibody Therapies (Joint)
Room: British/Columbia Ballroom

Speaker 5 of 7
Johannes vom Berg, University of Zürich, Switzerland
Short Talk: Local Interleukin-12 in Combination with Systemic Checkpoint Blockade Leads to T-Cell Dependent Rejection of Advanced Stage Glioma

Thursday, January 31 | 8:00AM - 11:15AM
Immunomodulatory Antibody Therapies (Joint)
Room: British/Columbia Ballroom

Speaker 6 of 7
Patrick A. Baeuerle, Amgen Research (Munich) GmbH, Germany
Immunotherapy with BiTE® Antibodies: Lessons Learned from Blinatumomab

Thursday, January 31 | 8:00AM - 11:15AM
Immunomodulatory Antibody Therapies (Joint)
Room: British/Columbia Ballroom

Speaker 7 of 7
Bent Jakobsen, Immunocore Ltd., UK
IMCgp100: A Bispecific TCR Anti-CD3 Fusion for the Treatment of Malignant Melanoma

Thursday, January 31 | 9:30AM - 9:50AM
Coffee Break
Room: British/Columbia Foyer


Thursday, January 31 | 10:00AM - 10:00AM
On Own for Lunch and Recreation


Thursday, January 31 | 4:30PM - 5:00PM
Coffee Available
Room: British/Columbia Foyer


Thursday, January 31 | 5:00PM - 7:00PM
Anti-Cancer Antibodies
Room: Columbia Ballroom

Speaker 1 of 5
* Nils Lonberg, Canaan Partners, USA

Thursday, January 31 | 5:00PM - 7:00PM
Anti-Cancer Antibodies
Room: Columbia Ballroom

Speaker 2 of 5
George J. Weiner, University of Iowa, USA
Therapeutic Mechanisms of Monoclonal Antibodies

Thursday, January 31 | 5:00PM - 7:00PM
Anti-Cancer Antibodies
Room: Columbia Ballroom

Speaker 3 of 5
Timo K. van den Berg, Sanquin Blood Supply, Netherlands
Short Talk: CD47-SIRPalpha Interactions Form a Barrier for Antibody-Mediated Tumor Cell Destruction by Phagocytes

Thursday, January 31 | 5:00PM - 7:00PM
Anti-Cancer Antibodies
Room: Columbia Ballroom

Speaker 4 of 5
Ronald P. DeMatteo, Memorial Sloan-Kettering Cancer Center, USA
Combined Immunologic and Molecular Therapy for Cancer

Thursday, January 31 | 5:00PM - 7:00PM
Anti-Cancer Antibodies
Room: Columbia Ballroom

Speaker 5 of 5
Glenn Dranoff, Novartis Institutes for BioMedical Research, USA
Therapy-Induced Antibody Responses

Thursday, January 31 | 5:00PM - 7:00PM
Challenges and New Opportunities with Antibody Drugs
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 1 of 4
* Kerry A. Chester, University College London Cancer Institute, UK


Thursday, January 31 | 5:00PM - 7:00PM
Challenges and New Opportunities with Antibody Drugs
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 2 of 4
Ryan J. Watts, Denali Therapeutics Inc, USA
Engineering Bispecific Blood-Brain Barrier Crossing Antibodies


Thursday, January 31 | 5:00PM - 7:00PM
Challenges and New Opportunities with Antibody Drugs
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 3 of 4
Leo James, MRC Laboratory of Molecular Biology, UK
Intracellular Immunity and TRIM21


Thursday, January 31 | 5:00PM - 7:00PM
Challenges and New Opportunities with Antibody Drugs
This session is from Antibodies as Drugs
Room: British Ballroom

Speaker 4 of 4
Sripad Ram, University of Texas Southwestern Medical Center, USA
Short Talk: Multifocal Plane Microscopy Reveals Novel Intracellular Trafficking Pathways at the Blood-Brain Barrier with Implications to Antibody Delivery to the Brain


Thursday, January 31 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Pacific Ballroom


Thursday, January 31 | 8:00PM - 11:00PM
Entertainment
Room: Pacific Ballroom


Thursday, January 31 | 8:00PM - 11:00PM
Cash Bar
Room: Pacific Ballroom


Friday, February 01 | 10:25AM - 10:25AM
Departure


*Session Chair.